Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Toripalimab for Bladder Preservation in High-Risk NMIBC (HER2+)
ChiCTR2600125168Phase 2Not yet recruiting
- Sponsor
- Zhangzhou Municipal Hospital
- Start
- May 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and toripalimab in transitional cell carcinoma of the bladder (TCC), sponsored by Zhangzhou Municipal Hospital. Primary endpoint: 12-month event-free survival rate (EFS). Planned start May 2026; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2600125168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125168.